Retro Biosciences expands early trial for drug targeting Alzheimer’s, Parkinson’s
Retro Biosciences is expanding its phase 1 safety trial of RTR 242 by adding two higher-dose cohorts and increasing enrollment from 76 to 108 participants, a more than 42% rise. The trial is being conducted in Australia in healthy volunteers aged 18 to 65. The company claims RTR 242 is designed to r
<p>Retro Biosciences is expanding its phase 1 safety trial of RTR 242 by adding two higher-dose cohorts and increasing enrollment from 76 to 108 participants, a more than 42% rise. The trial is being conducted in Australia in healthy volunteers aged 18 to 65. The company claims RTR 242 is designed to r</p>